We previously reported that Toll-like receptor-2 (TLR2) agonists induce expression of a more limited repertoire of pro-inflammatory genes than TLR4 agonists. Murine macrophages stimulated with the TLR4 agonist, Escherichia coli lipopolysaccharide, induced signal transducer and activator of transcription 1 ('STAT1') tyrosine phosphorylation that was secondary to the autocrine/paracrine action of interferon (IFN)-β, an immediate early gene. In contrast, TLR2 agonists failed to activate IFN-β gene expression. TLR4-induced IFN-β mRNA was found to be MyD88-and PKR (double-stranded RNA-dependent protein kinase)-independent, but TIRAP (Toll/interleukin-1 receptor domain-containing adapter protein)/Mal (MyD88-adapter-like)-dependent. In the present paper, we outline the recent controversy over the role of TIRAP/Mal in TLR2 and TLR4 signalling in the context of the current molecular tools used for such studies. Collectively, our findings provide the first mechanistic basis for differential patterns of gene expression activated by TLR4 and TLR2 agonists.
Toll-like receptor 4 signalling: new perspectives on a complex signal-transduction problem Introduction
Lipopolysaccharide (LPS) is among the most inflammatory of bacterial products. It is a common integral structural component of the outer membrane of Gram-negative bacteria. A primary physiological consequence of LPSmacrophage interaction is the release of an amazing spectrum of soluble mediators, many of which are synthesized de novo. Specifically, a variety of cytokines, chemokines, lipid-derived mediators and oxygen-derived antibacterial products are among those released by LPS-stimulated macrophages. The intensity and longevity of inflammatory mediator production dictates whether a response will be protective or whether an overwhelming inflammatory response will ensue, as is often seen in Gram-negative sepsis. All of our studies, in vivo or in vitro, have focused on understanding how to regulate this system to augment or dampen the response. The following will summarize our findings and postulate mechanisms of Toll-like receptor (TLR) signalling, leading to gene expression.
IL-1, interleukin-1; TIR, Toll/IL-1 receptor; TIRAP, TIR domain-containing adapter protein; Mal, MyD88-adapter-like; RT, reverse transcription; TNF-α, tumour necrosis factor-α; Cox-2, cyclo-oxygenase-2; IFN, interferon; IP-10, IFN-inducible protein-10; ICSBP, IFN consensus sequence-binding protein; NF-κB, nuclear factor-κB; iNOS, inducible nitric oxide synthase; Pam3Cys, S- [2,3- 
bis(palmitoyloxy)-(2-R,S)-propyl]-N-palmitoyl-(R)-Cys-(S)-Ser-Lys4-
hydroxytrihydrochloride; MCP-5, monocyte chemoattractant protein 5; MAP, mitogen-activated protein; DN, dominant negative; CpG, 2 -deoxyribo(cytidine-phosphate-guanosine); IRF-3, interferon regulatory factor 3. 1 To whom correspondence should be addressed (e-mail svogel@som.umaryland.edu).
LPS-induced gene expression in macrophages requires interaction of multiple proteins within an 'LPS receptor complex'
Using macrophages from mice with natural or targeted mutations, we found that co-ordinate receptor utilization is required for optimal LPS-induced gene expression [1, 2] . For example, we have used peritoneal exudate macrophages from C3H/HeJ mice, which have a point mutation in the intracytoplasmic domain of the TLR4 receptor that precludes normal LPS signalling [3, 4] , as well as mice with a targeted mutation in TLR4 [5] . Using reverse transcription (RT)-PCR with Southern blot analysis or Northern blot analysis, we have shown that TLR4 is necessary for expression of all LPS-inducible genes examined, e.g. tumour necrosis factor-α (TNF-α), interleukin (IL)-12 p40, IL-12 p35, cyclooxygenase-2 (Cox-2), interferon (IFN)-inducible protein-10 (IP-10) and IFN consensus sequence-binding protein (ICSBP). Increasing the concentration of LPS to µg/ml levels fails to overcome this defect. Macrophages derived from mice with a targeted mutation in CD14, a soluble or glycosylphosphatidylinositol-anchored glycoprotein, are also very deficient in LPS-induced gene expression at low concentrations of LPS. However, in contrast with macrophages derived from TLR4-deficient mice (e.g. C3H/HeJ or TLR4 knockout mice), most genes can be induced in CD14 knockout macrophages by increasing the concentration of LPS [6] . However, certain genes, such as those for IP-10 and ICSBP, are extremely dependent upon the presence of CD14 for induction, since increasing the concentration of LPS does not compensate for and enable induction of gene expression. Similarly, in mice deficient in the expression of Mac-1, the predominant β2 integrin on the surface of macrophages, attenuation of LPS-induced Cox-2 and IL-12 mRNA and protein expression is observed [1, 2, 7] . We therefore proposed a model in which multiple proteins interact within a larger LPS receptor complex to elicit maximal signalling in response to LPS, not unlike the interactions among the various proteins associated with the T-cell receptor-CD3 signalling complex [1, 2] . Once engaged, the various receptor complex proteins are postulated to recruit into the complex additional co-receptors and their attending adapters/enzymes. Such a model predicts that a multi-component LPS signalling complex is required to elicit the full repertoire of LPSinducible genes, and that deletion of these ancillary signalling molecules from the complex alters expression of those genes that are downstream from the signals elicited by that pathway.
TLR4 signalling utilizes an MyD88-independent pathway for diversification of pro-inflammatory gene expression through the production and autocrine action of IFN-β
Only as recently as a few years ago, there was a relatively simple paradigm for TLR signalling: TLR2 or TLR4, like the IL-1 and IL-18 receptors, recruited MyD88 and, from there, a sequential cascade occurred that resulted in nuclear factor-κB (NF-κB) translocation and gene expression. However, the TLR4 agonist, Escherichia coli K235 LPS, was much more toxic in vivo than the LPS derived from Porphyromonas gingivalis (for a review, see [8] ). In vitro, the E. coli LPS strongly induced a large number of inflammatory cytokine and chemokine genes, whereas the TLR2 agonist, P. gingivalis LPS, induced some genes to a comparable extent while the steady-state levels of others were either less sustained over time, or were not inducible [9] . This led us to hypothesize that the repertoire of genes induced by TLR4 agonists as compared with TLR2 ones reflects differential engagement of signalling pathways. Shortly after these findings were published, Jones et al. [10] used TLR4 and TLR2 agonists derived from Mycobacteria and showed differential expression of inducible nitric oxide synthase (iNOS), also in mouse macrophages. This led to a close collaboration between our laboratories, which will be discussed below in the context of newer data also presented at the Toll-Like Receptors meeting at Novartis, Horsham, U.K., on 3 February 2003.
Another TLR2 agonist, a triacylated, synthetic lipopeptide, S- [2,3- 
bis(palmitoyloxy)-(2-R,S)-propyl]-N-palmitoyl-(R)-
Cys-(S)-Ser-Lys 4 -hydroxytrihydrochloride (Pam3Cys), as well as higher concentrations of the P. gingivalis were compared directly, focusing on three genes that were the most differentially expressed by TLR4 as compared with TLR2 agonists in the studies by Hirschfeld et al. [9] and Jones et al. [10] : IP-10, monocyte chemoattractant protein 5 (MCP-5) and iNOS [11] . Consistent with our previous findings, both of the TLR2 agonists elicited approximately the same levels of TNF-α and IL-1β mRNA, and yet induced MCP-5, IP-10 and iNOS mRNA very poorly compared with the TLR4 agonist, E. coli LPS. These differences could not be attributed to dose, kinetics, the genetic background of the mice being used, or to differential activation of mitogen-activated protein (MAP) kinases [11] . The latter indicated that this was a part of the 'core' signalling pathway shared by TLR2 and TLR4 signalling pathways. Similar differences in TLR2-and TLR4-induced cellular responses have since been reported using human monocytes [12] .
We began to ask what was known about the transcriptional requirements for these three genes: one common denominator was that IP-10, MCP-5, and iNOS were all dependent upon signal transducer and activator of transcription 1 (STAT1) activation for optimal transcriptional activation, and both iNOS and IP-10 had been shown to be dependent upon IFN-α/β for their expression [13] [14] [15] . Therefore we hypothesized that the TLR4, but not the TLR2, agonists would induce STAT1 phosphorylation. As had been reported by Gao et al. [13] , the TLR4 agonist, E. coli K235 LPS, induces delayed phosphorylation of STAT1 on tyrosine when compared with IFN-γ , the prototype STAT1-activating agent. However, neither of the TLR2 agonists induced STAT1 activation. Even at concentrations that were 10-100-fold more than those required to elicit TNFα or IL-1β gene expression, neither the synthetic Pam3Cys nor the natural P. gingivalis LPS [11] induced Stat1 tyrosine phosphorylation. In contrast, serine phosphorylation of STAT1 was found to be comparable between TLR4 and TLR2 agonists (S.H. Rhee, B.W. Jones, V. Toshchakov, S.N. Vogel and M. Fenton, unpublished work). Thus the failure to activate the STAT1-signalling pathway distinguishes TLR2 from TLR4 signalling.
LPS-induced STAT1 tyrosine phosphorylation was TLR4-dependent, as evidenced by the failure to induce it in macrophages derived from C3H/HeJ mice. Furthermore, the observed delay in LPS-induced STAT1 phosphorylation, as compared with IFN-γ , suggested that new protein synthesis was required. This was supported by the finding that LPS-induced STAT1 phosphorylation was inhibited by the protein-synthesis inhibitor, cycloheximide [11] .
Gao et al. [13] had also shown previously that a polyclonal antibody to type 1 IFNs would block LPS-induced STAT1 phosphorylation. We extended this by using monoclonal antibodies against either IFN-α or IFN-β, and found that only the anti-(IFN-β) antibody effectively blocked STAT1 tyrosine phosphorylation [11] . Therefore we hypothesized that IFN-β would be differentially induced by TLR4 agonists as measured against TLR2 ones. Indeed, under conditions where these three agonists all induced comparable levels of TNF-α mRNA, only the TLR4 agonist induced IFN-β mRNA in the RAW 264.7 cell line and in primary murine peritoneal exudate macrophages. In primary macrophages, IFN-β is one of the very earliest genes induced by LPS, peaking at 1 h of stimulation of macrophages. By 'overcycling' during RT-PCR, a weak induction of IFN-β mRNA by the TLR2 agonists is demonstrable, but is considerably less and more transient than that seen in response to E. coli LPS. These findings were confirmed using a human IFN-β promoter luciferase reporter construct in transiently transfected RAW 264.7 macrophages [11] .
TLR4-induced signalling is orchestrated by involvement of distinct adapter molecules
To dissect the role of the various signalling intermediates in the induction of IFN-β gene expression by LPS, we took advantage of mice with specific targeted mutations in genes that encode signalling molecules, as well as molecular approaches using dominant-negative constructs and inhibitory peptides to block the action of specific adaptor molecules. Using macrophages derived from MyD88 wild-type and knockout mice [16] , we found that the induction of both IFN-β gene expression and STAT1 tyrosine phosphorylation were MyD88-independent [11] . This implied that MyD88, the adaptor that is recruited to the Toll/IL-1 receptor (TIR) domain of all TLRs and the IL-1 and IL-18 receptors upon receptor activation, is not necessary for the induction of IFN-β by TLR4 engagement.
The existence of an MyD88-independent TLR-signalling pathway was first suggested in studies by Kawai et al. [16] , who demonstrated that macrophages from MyD88 knockout mice responded to LPS stimulation with delayed NF-κB translocation and phosphorylation of the MAP kinases. This led to the discovery of a second adapter molecule called TIRAP (TIR domain-containing adapter protein) or Mal (MyD88-adapter-like) that was found to be constitutively associated with TLR4, but not with TLR9, IL-1 receptor or the IL-18 receptor [17, 18] . Moreover, TIRAP/Mal was found to interact with MyD88. It was also shown that overexpression of a TIRAP/Mal construct bearing a mutation of a critical proline residue within the TIR domain [Pro 125 →His; a TIRAP/Mal dominant negative (DN) construct] or treatment of cells with a TIRAP/Mal inhibitory peptide (which consists of a Drosophila antennapedia sequence positioned at the N-terminal end of murine TIRAP amino acids 138-151, shown to block both TIRAP-and MyD88-dependent signalling by LPS [17] ) inhibited both TIRAP/Mal-and MyD88-mediated signalling [17, 18] . Using a human IFN-β promoter luciferase reporter construct transiently transfected into the RAW 264.7 murine macrophage cell line, we next tested the dependency on TIRAP/Mal using a TIRAP DN construct [17] . Under conditions where the reporter expression induced by LPS was greatly inhibited, the reporter activity induced by 2 -deoxyribo(cytidine-phosphateguanosine) (CpG) DNA, a TLR9 agonist, was not, in spite of the fact that the level of reporter construct expression induced by LPS is much greater than induced by the CpG DNA. The inhibition by the TIRAP/Mal DN construct was confirmed using the TIRAP inhibitory peptide described by Horng et al. [17] that blocked LPS-induced endogenous IFN-β gene expression in the RAW 264.7 macrophage cell line, but not CpG-induced IFN-β gene expression [11] . Thus the TLR4-dependent induction of IFN-β gene expression is MyD88-independent, but TIRAP/Mal-dependent. The TIRAP inhibitory peptide also blocked IP-10 and iNOS gene expression (D. Schilling, unpublished work).
In the paper by Horng et al. [17] , the double-stranded RNA-dependent protein kinase, PKR, was shown to be one downstream target of TIRAP/Mal. We took advantage of PKR knockout mice to evaluate the potential role of PKR in the TLR4-mediated signalling. IFN-β, as well as all of the IFN-β-dependent genes, was PKR-independent [11] . In support of this observation, we found no significant difference in the extent to which the endogenous substrate of PKR, eIF-2α, was phosphorylated in response to TLR4 as compared with TLR2 agonists [19] . Therefore it appears that PKR is not necessary for the IFN-β-mediated signalling.
A model for TLR4 versus TLR2 signalling, and an enigma
Our data support a model in which TLR4, but not TLR2, elicits IFN-β gene expression, which, when translated and secreted, acts in an autocrine/paracrine fashion to activate STAT1 that, in turn, contributes to the induction of genes not normally induced by TLR2 agonists (e.g. those encoding IP-10, MCP-5 and iNOS). This model is consistent with the data of Kawai et al. [20] , who showed that phosphorylation of interferon regulatory factor 3 (IRF-3), a trans-acting factor involved in virus-induced IFN-β [21] , is induced by TLR4, but not by TLR2, agonists. Our data using both the TIRAP/Mal DN construct and inhibitory peptide to block IFN-β gene expression would support a role for TIRAP/Mal in this process, but not for MyD88. However, this model has been complicated by two recent reports by Yamamoto et al. [22, 23] . These authors reported that macrophages derived from mice with a targeted mutation in TIRAP/Mal exhibit phosphorylation of IRF-3 when stimulated by LPS, and that macrophages from TIRAP/Mal-MyD88 double knockout mice produce reduced levels of IP-10 mRNA in response to LPS [22] . This would imply that TIRAP/Mal is not necessary for IFN-β or IP-10 expression, in contrast with our conclusions. In a separate publication, these authors also reported that a novel adapter, called 'TRIF' (TIR domaincontaining adapter inducing IFNs) activates the IFN-β promoter in an overexpression system, and that a TRIF DN mutant blocks TLR3-induced IFN-β gene expression [23] . No data were provided for an effect of the TRIF DN mutant on TLR4-mediated IFN-β gene expression. Therefore, even if we modify the model by the addition of TRIF (or some TRIF equivalent), it still does not get around the fact that IFN-β, as well as all the downstream genes, are inhibited by the TIRAP DN construct or TIRAP inhibitory peptide. 
Do we really know how the DN constructs or inhibitory peptides work?
Most of our assumptions and conclusions about the interactions of the molecules involved in TLR signalling are based on the use of DN mutants or inhibitory peptides as described in our studies. How do these inhibitors actually work? Figure 1 illustrates the potential mechanisms of action for the DN constructs and inhibitory peptides. Virtually all of the DN constructs are based on a proline-to-histidine substitution within the 'BB loop' of the TIR domain. When overexpressed, the adapter molecule encoded by the DN construct has lost the capacity to interact with its normal target through the critical proline residue. Assuming no major conformational change in the rest of the molecule, the protein expressed by the DN construct presumably retains the ability to interact with molecules that would normally bind outside of the BB loop, leading to their sequestration away from native adapter molecules. In contrast, the inhibitory peptide comprises amino acids flanking the critical proline residue in the BB loop of the specific adapter. In this case, we presume that the inhibitory peptide blocks the interaction of the native adapter with its natural target, but does not preclude the adapter from interacting with molecules through other distinct protein-protein interaction domains outside of the BB loop. The assumption in both of these approaches is that the inhibition is specific, although this has not been rigorously established. Given these caveats, a number of other possibilities exist that may explain our TIRAP/Mal DN construct or inhibitory peptide data. First, another adapter(s) can substitute for TIRAP/Mal in the TIRAP knockout mice to elicit IRF-3 phosphorylation. Our prediction is that there is a family of adapter molecules that mediate specific interactions with the individual TLRs. It is also possible that, in normal cells, there is an interaction between TIRAP and TRIF (or a TLR4-specific equivalent adaptor molecule) that is disrupted by expression of the TIRAP/Mal DN construct or inhibitory peptide, and can be overcome by overexpression of TRIF. Finally, it is possible that the mechanism of action of the DN or inhibitory peptides is different from the mechanisms proposed in Figure 1 , and we will have to develop more specific inhibitors to dissect the various adapter-TLR interactions.
In summary, our work clearly establishes that the induction of IFN-β through an MyD88-independent pathway contributes to the unique signalling elicited by TLR4 agonists. IFN-β, through an autocrine/paracrine interactions with the IFN-α/β receptor on the surface of cells, generates tyrosine-phosphorylated STAT1, which, in turn, can participate as a transactivating molecule in the expression of a number of STAT1-dependent genes that are not elicited upon TLR2 stimulation.
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